Table 3. Incidence rates of statistically significant mutations and biomarkers in TP53-MT (n=28) tumors versus TP53-WT (n=238).
| Alteration | Test | TP53-MT (n=28) incidence (%) | TP53-MT incidence ratio | TP53-WT (n=238) incidence (%) | TP53-WT incidence ratio | P value |
|---|---|---|---|---|---|---|
| Tumor suppressor genes | ||||||
| CDKN2A | NGS | 24 | 6/25 | 0 | 0/191 | 0.0000 |
| Immune | ||||||
| APC | NGS | 20 | 5/25 | 1.6 | 3/187 | 0.0007 |
| APC | NGS hot spot | 33.33 | 1/3 | 0 | 0/59 | 0.0484 |
| RAS/RAF/MEK | ||||||
| BRAF | NGS | 8 | 2/25 | 0 | 0/192 | 0.0128 |
| PI3K related kinases | ||||||
| PIK3CA | NGS | 8 | 2/25 | 30.6 | 60/196 | 0.0178 |
| Other | ||||||
| NOTCH1 | NGS | 12 | 3/25 | 2.23 | 4/179 | 0.0410 |
| CAL-R | CNA | 8.33 | 2/24 | 0.55 | 1/181 | 0.0367 |
| FGFR1 | CNA | 8.33 | 2/24 | 0 | 0/185 | 0.0127 |
| ZNF703 | CNA | 8.33 | 2/24 | 0.55 | 1/170 | 0.0409 |
TP53-MT, TP53-mutated; TP53-WT, TP53-wild type; NGS, next-generation sequencing; CNA, copy number alteration.